It also showed diminished viability (p < 0.001) of the HeLa-PTX-R cells with the combination treatment [PTX (4 nM) + GRg5 (20 μM)] compared to GRg5 (20 μM) alone (Figure 3a–d), we have also tested the PTX drug alone and combination with GRg5 in normal Hela cells, that too confirmed the good efficacy of PTX in treating cancer cells when combined with GRg5 (Figure 3e–h). The gene discussed is TLE5; the disease is cancer.